Persistent Damage to the Gut Microbiome following Messenger RNA **SARS-CoV-2 Vaccine** PROGENABIOME Sabine Hazan¹, Sonya Davé², Thomas J. Borody³

¹ProgenaBiome, LLC, Ventura, CA, USA, ²Microbiome Research Foundation, Ventura, CA, USA, ³Centre for Digestive Diseases, Five Dock, NSW, AUS

Introduction

- The human gut microbiome is an essential determinant of human health.
- Bifidobacterium decline is inflammatory bowel disease, obesity, neurological disorders, C. diffícile infection and severe COVID-19 (1-3).
- Long-term effect of messenger RNA vaccines for SARS-CoV-2 on the human gut microbiome is unknown.
- The purpose of this study was to explore longitudinal changes in the Relative Abundance of Bifidobacterium after mRNA SARS-CoV-2 vaccination.
- Bifidobacterium below pre-vaccination levels.
- Bifidobacterium below pre-vaccination levels.
- No subjects exhibited significant post-vaccine complications.
- Bifidobacterium via oral or fecal transplant routes.

References

- Ruiz L, et al. Front Microbiol. 2017;8:2345.
- Suganya K, Koo BS. Int J Mol Sci. 2020;21(20):7551.
- Hazan S, et al. BMJ Open Gastro. 2022;9(1):e000871.

Methods

associated with

We longitudinally recorded the Relative Abundance of Bifidobacterium in four subjects before receiving a mRNA vaccine (Pfizer or Moderna) for SARS-CoV-2, approximately one post-vaccination, as well as 6-9 months post-vaccination. Additional SARS-CoV-2 vaccines were given during that period, totaling 2 to 3 doses. Samples were collected at the time points mentioned. No dietary changes or new medications were introduced throughout the study period. Metagenomic next generation sequencing-based methods were applied to samples obtained from fecal collection. DNA was extracted, and the library prepped, enriched and sequenced on an Illumina Nextseq 550 system. This study was IRB approved.

Discussion

At 1 month post-vaccination, 3 of 4 subjects experienced a decrease

At 6-9 months post-vaccination, all subjects experienced a decrease

The lasting decrease in Bifidobacterium levels may contribute to SARS-CoV-2 inf Gut dysbiosis after mRNA SARS-CoV-2 vaccination may be a future indication for restoration of

in	Relative	Abundance	of		
in	Relative	Abundance	of		
nfection post vaccination.					

Subject	
1	
2	
3	
4	
Table 1. Ch SARS-CoV-2	2
4.	
rium ndance	
dobacte ve Abul	

Bifi elati

Ŕ

Figure 1. Decline in Relative Abundance of *Bifidobacterium* after SARS-CoV-2 mRNA vaccination.

Abstract E0141 (S2108)

Results				
Change in Relative Abundance of <i>Bifidobacterium</i> (% of pre-vaccine level)				
1 month post-vaccine	6-9 months post-vaccine			
38%	15%			
258%	0%			
49%	35%			
90%	60%			

ange in Relative Abundance of *Bifidobacterium* after 2 mRNA vaccination.

